Structures and Manufacturing Support
BioPharm International-09-01-2011
PDUFA renewal legislation sets stage for new policies affecting revenue, research, and oversight.
The author reviews the state of downstream processing, including a look at the streamlining of full processes and borrowed technologies.
Why SOPs are rarely followed, often cited, and in great need of follow-through.
The author describes recent developments to help overcome the downstream-processing bottleneck.
How to strike a balance between site autonomy and global coordination.
A report commissioned by FDA evaluates the QbD paradigm.
The EU debt crisis portends of possible negative repercussions for the dose CMO industry.
FDA weighs multiple views regarding the Biologics Price Competition and Innovation Act.
Advertisement
Advertisement
Trending on BioPharm International
1
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
2
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
3
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
4
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
5
